These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 20686240)

  • 1. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies.
    Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K
    Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.
    Ito T; Tsumoto K
    Protein Sci; 2013 Nov; 22(11):1542-51. PubMed ID: 23963869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
    Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
    J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R409K mutation prevents acid-induced aggregation of human IgG4.
    Namisaki H; Saito S; Hiraishi K; Haba T; Tanaka Y; Yoshida H; Iida S; Takahashi N
    PLoS One; 2020; 15(3):e0229027. PubMed ID: 32182240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid-induced aggregation propensity of nivolumab is dependent on the Fc.
    Liu B; Guo H; Xu J; Qin T; Xu L; Zhang J; Guo Q; Zhang D; Qian W; Li B; Dai J; Hou S; Guo Y; Wang H
    MAbs; 2016; 8(6):1107-17. PubMed ID: 27310175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of IgG subclass on monoclonal antibody developability.
    Cain P; Huang L; Tang Y; Anguiano V; Feng Y
    MAbs; 2023; 15(1):2191302. PubMed ID: 36945111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-angle x-ray scattering screening complements conventional biophysical analysis: comparative structural and biophysical analysis of monoclonal antibodies IgG1, IgG2, and IgG4.
    Tian X; Langkilde AE; Thorolfsson M; Rasmussen HB; Vestergaard B
    J Pharm Sci; 2014 Jun; 103(6):1701-10. PubMed ID: 24700358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.
    Saito S; Namisaki H; Hiraishi K; Takahashi N; Iida S
    Protein Sci; 2019 May; 28(5):900-909. PubMed ID: 30834577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational implications of an inversed pH-dependent antibody aggregation.
    Perico N; Purtell J; Dillon TM; Ricci MS
    J Pharm Sci; 2009 Sep; 98(9):3031-42. PubMed ID: 18803243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species.
    Zheng S; Qiu D; Adams M; Li J; Mantri RV; Gandhi R
    AAPS PharmSciTech; 2017 Jan; 18(1):42-48. PubMed ID: 26340951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both Reversible Self-Association and Structural Changes Underpin Molecular Viscoelasticity of mAb Solutions.
    Sarangapani PS; Weaver J; Parupudi A; Besong TMD; Adams GG; Harding SE; Manikwar P; Castellanos MM; Bishop SM; Pathak JA
    J Pharm Sci; 2016 Dec; 105(12):3496-3506. PubMed ID: 27793346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrasonic rheology of a monoclonal antibody (IgG2) solution: implications for physical stability of proteins in high concentration formulations.
    Saluja A; Badkar AV; Zeng DL; Kalonia DS
    J Pharm Sci; 2007 Dec; 96(12):3181-95. PubMed ID: 17588261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the chromatographic properties of IgG1 and IgG2 antibody subclasses.
    Ghose S; Ladwig J; Allen M
    Biotechnol Appl Biochem; 2010 Dec; 57(3):111-6. PubMed ID: 20874708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity selection, screening and quantitative structure-activity relationships of osmolyte-like additive effects on the thermal stability of a monoclonal antibody.
    Oyetayo OO; Méndez-Lucio O; Bender A; Kiefer H
    Eur J Pharm Sci; 2017 Jan; 97():151-157. PubMed ID: 27866015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibodies Follow Distinct Aggregation Pathways During Production-Relevant Acidic Incubation and Neutralization.
    Skamris T; Tian X; Thorolfsson M; Karkov HS; Rasmussen HB; Langkilde AE; Vestergaard B
    Pharm Res; 2016 Mar; 33(3):716-28. PubMed ID: 26563206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
    Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
    J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation.
    Gandhi S; Ren D; Xiao G; Bondarenko P; Sloey C; Ricci MS; Krishnan S
    Pharm Res; 2012 Jan; 29(1):209-24. PubMed ID: 21845507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
    Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
    Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.